The Company is now recognized by the U.S. FDA to support the cross-border supply of GMP MDMA and psilocybin to authorized entities in the United States. Vancouver, British Columbia–(Newsfile Corp. – May 5, 2025) – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (“Optimi” or the “Company”), a manufacturer …
Read More »Optimi Health Provides Corporate Update
Vancouver, British Columbia–(Newsfile Corp. – March 12, 2025) – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (“Optimi” or the “Company”), a GMP-compliant, Health Canada-licensed manufacturer specializing in botanical psilocybin and MDMA, is pleased to provide the following corporate update, highlighting key regulatory milestones, clinical trial progress, and expanded …
Read More »Optimi Health Completes Largest MDMA Capsule Batch to Date, Expands Stability Program
Over 4,000 GMP Capsules Ready to Support PTSD Treatment in Australia, Israel, and Canada Vancouver, British Columbia–(Newsfile Corp. – January 29, 2025) – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (“Optimi” or the “Company”), a Canadian-based company licensed by Health Canada to produce and supply natural, GMP-grade psilocybin …
Read More »Optimi Health Announces Closing of Non-Brokered Private Placement and Debt Settlement
Vancouver, British Columbia–(Newsfile Corp. – January 28, 2025) – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (“Optimi” or the “Company”), a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, announces it has closed the second and final tranche (the “Second Tranche”) of its …
Read More »
Matribhumi Samachar English